インドネシアの体外診断市場：2027 年までの予測

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2022年9月

Indonesia In-Vitro Diagnostics Market Research Report Forecast to 2027
インドネシアの体外診断市場調査レポート：2027 年までの予測

レポート目次　　　　お問合せ・ご注文　　　　価格・納期について

Indonesia In-Vitro Diagnostics Market Research Report Forecast to 2027

Market OVERVIEW
In-vitro diagnostics (IVD) are medical devices, reagents, and accessories used to perform tests on samples, (e.g., blood, urine, and tissue) taken from the human body to help detect infection, diagnose a medical condition, and prevent disease. IVD plays a major role in the early diagnosis and management of diseases. The key factors that drive the Indonesia in-vitro diagnostics market are rising prevalence of chronic & infectious diseases and growing awareness of personalized medicine. However, an unfavorable reimbursement scenario is anticipated to hamper the market growth.
In-vitro diagnostics (IVDs) are non-invasive tests performed on biological samples (for example, blood, urine, or tissues) to diagnose a disease. IVDs provide valuable information on the body’s functioning and state of health. IVD is used for the diagnosis, screening, and therapeutic monitoring of diseases. IVDs have a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple self-tests, such as those for pregnancy and glucose monitoring.
The Indonesia in-vitro diagnostics market is emerging due to the high prevalence of chronic and infectious diseases, increasing adoption of point-of-care testing, and rising collaborations between private and public organizations for the development of the healthcare sector are responsible for the growth of the Indonesia in-vitro diagnostics market. However, regulatory procedures for high/moderate-complexity tests and information and interest gap between investors and developers are likely to restrain the market growth during the forecast period. The scope of the Indonesia in-vitro diagnostics market study includes market size analysis and a detailed analysis of the manufacturer’s products and service strategies.
Market Segmentation
The market has been segmented based on product & services, technology, application and end user.
The Indonesia in-vitro diagnostics market is segmented on the basis of product & services into reagents & kits, instruments, data management, and software & services. The instruments segment is further segmented into fully automated instruments and semi-automated instruments.
The Indonesia in-vitro diagnostics market is segmented on the basis of technology into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hemostasis, hematology, and others. The others segment includes microbiology and tissue diagnostics.
Based on application, the Indonesia in-vitro diagnostics market is bifurcated into infectious diseases oncology, cardiology, autoimmune diseases, nephrology, diabetes, HIV-AIDS, drug testing, and pharmacogenomics.
Based on end user, the Indonesia in-vitro diagnostics market is segmented into hospitals, laboratories, point-of-care testing, academic institutes, and others.
Major Players
The key players of the Indonesia in-vitro diagnostics market are BD, Bio-rad Laboratories, Thermo Fisher Scientific, Biomeruix SA, and Danaher Corporation.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

TABLE OF CONTENTS
1EXECUTIVE SUMMARY
1.1OVERVIEW
2MARKET INTRODUCTION
2.1SCOPE OF THE STUDY
2.2RESEARCH OBJECTIVE
2.3MARKET STRUCTURE
2.4ASSUMPTIONS & LIMITATIONS
3RESEARCH METHODOLOGY
3.1DATA MINING
3.2SECONDARY RESEARCH
3.3PRIMARY RESEARCH
3.4BREAKDOWN OF PRIMARY RESPONDENTS
3.5FORECASTING TECHNIQUES
3.6RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1BOTTOM-UP APPROACH
3.6.2TOP-DOWN APPROACH
3.7DATA TRIANGULATION
3.8VALIDATION
4MARKET DYNAMICS
4.1OVERVIEW
4.2DRIVERS
4.2.1HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.2INCREASING ADOPTION OF POINT-OF-CARE TESTING
4.2.3RISING COLLABORATIONS BETWEEN PRIVATE AND PUBLIC ORGANIZATIONS FOR THE DEVELOPMENT OF THE HEALTHCARE SECTOR
4.3RESTRAINTS
4.3.1REGULATORY PROCEDURES FOR HIGH/MODERATE-COMPLEXITY TESTS
4.3.2INFORMATION AND INTEREST GAP BETWEEN INVESTORS AND DEVELOPERS
4.4OPPORTUNITY
4.4.1GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS
5MARKET FACTOR ANALYSIS
5.1VALUE CHAIN ANALYSIS
5.1.1R&D
5.1.2MANUFACTURING
5.1.3DISTRIBUTION AND SALES
5.1.4POST-SALES MONITORING
5.2PORTER’S FIVE FORCES MODEL
5.2.1BARGAINING POWER OF SUPPLIERS
5.2.2BARGAINING POWER OF BUYERS
5.2.3THREAT OF NEW ENTRANTS
5.2.4THREAT OF SUBSTITUTES
5.2.5INTENSITY OF RIVALRY
5.3IMPACT OF COVID-19 ON THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
5.3.1IMPACT ON SUPPLY CHAIN
5.3.2IMPACT ON MARKET
5.3.3IMPACT ON R&D
6INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES
6.1OVERVIEW
6.2REAGENTS & KITS
6.3INSTRUMENTS
6.4DATA MANAGEMENT
6.5SOFTWARE & SERVICES
7INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1OVERVIEW
7.2IMMUNOASSAY/IMMUNOCHEMISTRY
7.3CLINICAL CHEMISTRY
7.4MOLECULAR DIAGNOSTICS
7.5HEMOSTASIS
7.6HEMATOLOGY
7.7OTHERS
8INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
8.1OVERVIEW
8.2INFECTIOUS DISEASES
8.3DIABETES
8.4ONCOLOGY
8.5CARDIOLOGY
8.6AUTOIMMUNE DISEASES
8.7HIV/AIDS
8.8DRUG TESTING
8.9NEPHROLOGY
8.10PHARMACOGENOMICS
8.11OTHERS
9INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER
9.1OVERVIEW
9.2HOSPITALS
9.3LABORATORIES
9.4POINT-OF-CARE TESTING
9.5ACADEMIC INSTITUTES
9.6OTHERS
10COMPETITIVE LANDSCAPE
10.1COMPETITIVE OVERVIEW
10.2MAJOR PLAYERS IN THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
10.3COMPETITIVE BENCHMARKING
10.4MAJOR PLAYERS FINANCIAL MATRIX
10.4.1REVENUE OF MAJOR PLAYERS, 2020
10.4.2R&D EXPENDITURE, 2020
11COMPANY PROFILES
11.1F. HOFFMANN-LA ROCHE LTD
11.1.1COMPANY OVERVIEW
11.1.2FINANCIAL OVERVIEW
11.1.3PRODUCTS/SERVICES OFFERED
11.1.4KEY DEVELOPMENTS
11.1.5SWOT ANALYSIS
11.1.6KEY STRATEGIES
11.2SYSMEX CORPORATION
11.2.1COMPANY OVERVIEW
11.2.2FINANCIAL OVERVIEW
11.2.3PRODUCTS/SERVICES OFFERED
11.2.4KEY DEVELOPMENTS
11.2.5KEY STRATEGIES
11.3DANAHER CORPORATION
11.3.1COMPANY OVERVIEW
11.3.2FINANCIAL OVERVIEW
11.3.3PRODUCTS/SERVICES OFFERED
11.3.4KEY DEVELOPMENTS
11.3.5SWOT ANALYSIS
11.3.6KEY STRATEGIES
11.4BIO-RAD LABORATORIES, INC.
11.4.1COMPANY OVERVIEW
11.4.2FINANCIAL OVERVIEW
11.4.3PRODUCTS/SERVICES OFFERED
11.4.4KEY DEVELOPMENTS
11.4.5SWOT ANALYSIS
11.4.6KEY STRATEGIES
11.5BIOMÉRIEUX SA
11.5.1COMPANY OVERVIEW
11.5.2FINANCIAL OVERVIEW
11.5.3PRODUCTS/SERVICES OFFERED
11.5.4KEY DEVELOPMENTS
11.5.5KEY STRATEGIES
11.6BECTON, DICKINSON AND COMPANY
11.6.1COMPANY OVERVIEW
11.6.2FINANCIAL OVERVIEW
11.6.3PRODUCTS/SERVICES OFFERED
11.6.4KEY DEVELOPMENTS
11.6.5SWOT ANALYSIS
11.6.6KEY STRATEGIES
11.7SIEMENS
11.7.1COMPANY OVERVIEW
11.7.2FINANCIAL OVERVIEW
11.7.3PRODUCTS/SERVICES OFFERED
11.7.4KEY DEVELOPMENTS
11.7.5KEY STRATEGIES
11.8THERMO FISHER SCIENTIFIC, INC.
11.8.1COMPANY OVERVIEW
11.8.2FINANCIAL OVERVIEW
11.8.3PRODUCTS OFFERED
11.8.4KEY DEVELOPMENTS
11.8.5SWOT ANALYSIS
11.8.6KEY STRATEGIES
11.9QIAGEN
11.9.1COMPANY OVERVIEW
11.9.2FINANCIAL OVERVIEW
11.9.3PRODUCTS/SERVICES OFFERED
11.9.4KEY DEVELOPMENTS
11.9.5KEY STRATEGIES
11.10AGILENT TECHNOLOGIES
11.10.1COMPANY OVERVIEW
11.10.2FINANCIAL OVERVIEW
11.10.3PRODUCTS/SERVICES OFFERED
11.10.4KEY DEVELOPMENTS
11.10.5KEY STRATEGIES
12APPENDIX
12.1REFERENCES
12.2RELATED REPORTS

LIST OF TABLES
TABLE 1LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2018–2027 (USD MILLION)
TABLE 4INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY REAGENTS & KITS, 2018–2027 (USD MILLION)
TABLE 5INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY INSTRUMENTS, 2018–2027 (USD MILLION)
TABLE 6INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR INSTRUMENTS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 7INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DATA MANAGEMENT, 2018–2027 (USD MILLION)
TABLE 8INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY SOFTWARE & SERVICES, 2018–2027 (USD MILLION)
TABLE 9INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)
TABLE 10INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY IMMUNOASSAY/IMMUNOCHEMISTRY, 2018–2027 (USD MILLION)
TABLE 11INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2018–2027 (USD MILLION)
TABLE 12INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY CLINICAL CHEMISTRY, 2018–2027 (USD MILLION)
TABLE 13INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY MOLECULAR DIAGNOSTICS, 2018–2027 (USD MILLION)
TABLE 14INDONESIA IN-VITRO DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2018–2027 (USD MILLION)
TABLE 15INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HEMOSTASIS, 2018–2027 (USD MILLION)
TABLE 16INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HEMATOLOGY, 2018–2027 (USD MILLION)
TABLE 17INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 18INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
TABLE 19INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2018–2027 (USD MILLION)
TABLE 20INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DIABETES, 2018–2027 (USD MILLION)
TABLE 21INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DIABETES, 2018–2027 (USD MILLION)
TABLE 22INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY CARDIOLOGY, 2018–2027 (USD MILLION)
TABLE 23INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY AUTOIMMUNE DISEASES, 2018–2027 (USD MILLION)
TABLE 24INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HIV/AIDS, 2018–2027 (USD MILLION)
TABLE 25INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY DRUG TESTING, 2018–2027 (USD MILLION)
TABLE 26INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY NEPHROLOGY, 2018–2027 (USD MILLION)
TABLE 27INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PHARMACOGENOMICS, 2018–2027 (USD MILLION)
TABLE 28INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 29INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2018–2027 (USD MILLION)
TABLE 30INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY HOSPITALS, 2018–2027 (USD MILLION)
TABLE 31INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY LABORATORIES, 2018–2027 (USD MILLION)
TABLE 32INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY POINT-OF-CARE TESTING, 2018–2027 (USD MILLION)
TABLE 33INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY ACADEMIC INSTITUTES, 2018–2027 (USD MILLION)
TABLE 34INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY OTHERS, 2018–2027 (USD MILLION)
TABLE 35MAJOR PLAYERS IN THE INDONESIA IN-VITRO DIAGNOSTICS MARKET
TABLE 36F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
TABLE 37SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 38DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 39BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 40BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED
TABLE 41BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 42SIEMENS: PRODUCTS/SERVICES OFFERED
TABLE 43THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 44QIAGEN: PRODUCTS/SERVICES OFFERED
TABLE 45AGILENT TECHNOLOGIES: PRODUCTS/SERVICES OFFERED

FIGURE 1MARKET SYNOPSIS11
FIGURE 2MARKET STRUCTURE: INDONESIA IN-VITRO DIAGNOSTICS MARKET12
FIGURE 3BOTTOM-UP AND TOP-DOWN APPROACHES19
FIGURE 4MARKET DYNAMICS: INDONESIA IN-VITRO DIAGNOSTICS MARKET22
FIGURE 5VALUE CHAIN ANALYSIS: INDONESIA IN-VITRO DIAGNOSTICS MARKET27
FIGURE 6PORTER’S FIVE FORCES ANALYSIS: INDONESIA IN-VITRO DIAGNOSTICS MARKET29
FIGURE 7INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2020 & 2027 (USD MILLION)32
FIGURE 8INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 & 2027 (USD MILLION)35
FIGURE 9INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION)41
FIGURE 10INDONESIA IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020 & 2027 (USD MILLION)45
FIGURE 11BENCHMARKING OF MAJOR COMPETITORS49
FIGURE 12REVENUE OF MAJOR PLAYERS, 202050
FIGURE 13MAJOR PLAYERS R&D EXPENDITURE, 202050
FIGURE 14F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT52
FIGURE 15F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS53
FIGURE 16SYSMEX CORPORATION: FINANCIAL OVERVIEW SNAPSHOT55
FIGURE 17DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT58
FIGURE 18DANAHER CORPORATION: SWOT ANALYSIS59
FIGURE 19BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT61
FIGURE 20BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS62
FIGURE 21BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT64
FIGURE 22BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT67
FIGURE 23BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS68
FIGURE 24SIEMENS: FINANCIAL OVERVIEW SNAPSHOT70
FIGURE 25THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT73
FIGURE 26THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS74
FIGURE 27QIAGEN: FINANCIAL OVERVIEW76
FIGURE 28AGILENT TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT79